Citadel Advisors
TAK icon

Citadel Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Citadel Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Sell
168,128
-456,032
-73% -$7.55M ﹤0.01% 5896
2026
Q1 		$11.6M Buy
624,160
+234,426
+60% +$4.11M ﹤0.01% 3052
2025
Q4 		$6.08M Buy
389,734
+314,110
+415% +$4.49M ﹤0.01% 3978
2025
Q3 		$1.11M Buy
+75,624
New +$1.12M ﹤0.01% 7317
2025
Q2 		– Sell
-142,556
Closed -$2.11M – 15019
2025
Q1 		$2.12M Buy
142,556
+104,567
+275% +$1.47M ﹤0.01% 5424
2024
Q4 		$503K Buy
+37,989
New +$522K ﹤0.01% 8542
2024
Q3 		– Sell
-312,081
Closed -$4.43M – 15226
2024
Q2 		$4.04M Buy
312,081
+302,886
+3,294% +$4.01M ﹤0.01% 4085
2024
Q1 		$128K Sell
9,195
-86,564
-90% -$1.26M ﹤0.01% 11016
2023
Q4 		$1.37M Buy
95,759
+92,068
+2,494% +$1.31M ﹤0.01% 6060
2023
Q3 		$57.1K Sell
3,691
-44,584
-92% -$690K ﹤0.01% 11593
2023
Q2 		$758K Sell
48,275
-7,741
-14% -$127K ﹤0.01% 7033
2023
Q1 		$923K Buy
56,016
+36,273
+184% +$578K ﹤0.01% 6956
2022
Q4 		$308K Sell
19,743
-678,082
-97% -$9.47M ﹤0.01% 9263
2022
Q3 		$9.05M Buy
697,825
+296,059
+74% +$4.12M ﹤0.01% 2911
2022
Q2 		$5.64M Buy
401,766
+58,083
+17% +$829K ﹤0.01% 3574
2022
Q1 		$4.92M Sell
343,683
-18,335
-5% -$269K ﹤0.01% 4202
2021
Q4 		$4.93M Sell
362,018
-37,960
-9% -$532K ﹤0.01% 4315
2021
Q3 		$6.55M Buy
399,978
+76,288
+24% +$1.28M ﹤0.01% 3794
2021
Q2 		$5.45M Buy
323,690
+110,412
+52% +$1.88M ﹤0.01% 4248
2021
Q1 		$3.9M Sell
213,278
-140,122
-40% -$2.52M ﹤0.01% 4826
2020
Q4 		$6.43M Buy
353,400
+231,403
+190% +$4.06M ﹤0.01% 3253
2020
Q3 		$2.18M Buy
121,997
+15,394
+14% +$280K ﹤0.01% 4562
2020
Q2 		$1.91M Sell
106,603
-98,434
-48% -$1.77M ﹤0.01% 4666
2020
Q1 		$3.11M Buy
205,037
+108,154
+112% +$1.96M ﹤0.01% 3403
2019
Q4 		$1.91M Sell
96,883
-98,211
-50% -$1.88M ﹤0.01% 4488
2019
Q3 		$3.36M Buy
195,094
+25,788
+15% +$446K ﹤0.01% 3675
2019
Q2 		$3M Buy
169,306
+121,028
+251% +$2.2M ﹤0.01% 3859
2019
Q1 		$983K Sell
48,278
-528,806
-92% -$10.6M ﹤0.01% 5620
2018
Q4 		$9.71M Buy
+577,084
New +$9.74M 0.01% 1928

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citadel Advisors's TAK Position: Q2 2026 in Review

Citadel Advisors reduced its Takeda Pharmaceutical (TAK) stake by 73% in Q2 2026, selling an estimated $7.55M and leaving 168,128 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #5896.

Citadel Advisors first reported a position in TAK in Q4 2018 and has held it in 29 quarters since. The position peaked at $11.6M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Citadel Advisors held 168,128 shares of Takeda Pharmaceutical worth $2.7M as of Q2 2026.
  • Citadel Advisors sold 456,032 Takeda Pharmaceutical shares in Q2 2026, an estimated $7.55M.
  • Takeda Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5896 holding.
  • Citadel Advisors first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Takeda Pharmaceutical position peaked at $11.6M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.